CJC-1295 No DAC 5mg / Ipamorelin 10mg (15mg Blend)

CJC-1295 and Ipamorelin are two synthetic peptides combined in a single multi-compound research formulation for laboratory and preclinical investigation. Each compound is characterized by its interaction with distinct receptor pathways associated with growth hormone–related signaling mechanisms in non-human experimental models. In controlled research environments, this combined formulation is utilized to examine comparative receptor engagement, signaling pathway behavior, and peptide–receptor interaction dynamics when multiple compounds are present within the same experimental system. The formulation supports analytical investigation of concurrent signaling activity and pathway coordination under standardized laboratory conditions. The combined presence of CJC-1295 and Ipamorelin allows researchers to study parallel peptide signaling characteristics, receptor selectivity, and temporal signaling patterns without implying additive, synergistic, or outcome-oriented effects. This research format is intended solely to support pathway analysis and signaling characterization in non-human laboratory models. This material is supplied exclusively for research and analytical use and is not intended for human consumption, diagnosis, treatment, or therapeutic application.   Summary of Characteristics Attribute CJC-1295 Ipamorelin Chemical Sequence of Amino Acids Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu Aib-His-D-2-Nal-D-Phe-Lys-NH₂ Molecular Formula C165H269N47O46 C38H49N9O5 Molecular Weight 3,647.19 g/mol 711.85 g/mol CAS Number 863288-34-0 170851-70-4 Other Known Titles GHRH analog (research designation) Ghrelin receptor agonist (research designation)